Concert Pharmaceuticals Performance
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
The firm shows a Beta (market volatility) of 1.41, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Concert Pharmaceuticals will likely underperform. Concert Pharmaceuticals right now shows a risk of 0.0%. Please confirm Concert Pharmaceuticals total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to decide if Concert Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Concert Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Concert Pharmaceuticals is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 78.4 M | |
| Total Cashflows From Investing Activities | 52.5 M |
Concert |
Concert Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Concert Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of 100.00 from holding Concert Pharmaceuticals or generate -100.0% return on investment over 90 days. Concert Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Concert, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Concert Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Concert Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Concert Pharmaceuticals, and traders can use it to determine the average amount a Concert Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CNCE |
Based on monthly moving average Concert Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Concert Pharmaceuticals by adding Concert Pharmaceuticals to a well-diversified portfolio.
Concert Pharmaceuticals Fundamentals Growth
Concert Stock prices reflect investors' perceptions of the future prospects and financial health of Concert Pharmaceuticals, and Concert Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Concert Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X | |||
| Price To Sales | 7.05 X | |||
| Revenue | 32.58 K | |||
| EBITDA | 1.4 M | |||
| Cash And Equivalents | 154.57 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 14.51 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (55.15 M) | |||
| Earnings Per Share | (3.17) X | |||
| Total Asset | 165.32 M | |||
| Retained Earnings | (210.05 M) | |||
| Current Asset | 144.11 M | |||
| Current Liabilities | 6.63 M | |||
About Concert Pharmaceuticals Performance
By analyzing Concert Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Concert Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Concert Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Concert Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. Concert Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.Things to note about Concert Pharmaceuticals performance evaluation
Checking the ongoing alerts about Concert Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Concert Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Concert Pharmaceuticals is not yet fully synchronised with the market data | |
| Concert Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 32.58 K. Net Loss for the year was (80.05 K) with loss before overhead, payroll, taxes, and interest of (54.98 M). | |
| Concert Pharmaceuticals currently holds about 154.57 M in cash with (55.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Concert Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Concert Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Concert Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Concert Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Concert Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Concert Pharmaceuticals' stock. These opinions can provide insight into Concert Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |